BEDORADRINE

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C24H32N2O5
Molecular Weight	428.5213
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN(C)C(=O)COC1=CC=C2CC[C@@H](CC2=C1)NC[C@H](O)C3=CC=C(O)C(CCO)=C3

InChI

InChIKey=OANCEOSLKSTLTA-REWPJTCUSA-N

InChI=1S/C24H32N2O5/c1-26(2)24(30)15-31-21-7-4-16-3-6-20(12-19(16)13-21)25-14-23(29)17-5-8-22(28)18(11-17)9-10-27/h4-5,7-8,11,13,20,23,25,27-29H,3,6,9-10,12,14-15H2,1-2H3/t20-,23-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C24H32N2O5
Molecular Weight	428.5213
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26324315 | https://www.kissei.co.jp/e_contents/relation/annual_report/uploaded/kissei_ar2013.pdf | https://clinicaltrials.gov/ct2/show/NCT01551316

Bedoradrine (also known as KUR-1246 or MN-221), an ultra selective beta 2-adrenoceptor agonist, that participated in phase II clinical trials as an adjunct to standard therapy in the management of patients with acute exacerbation of asthma who did not respond to standard therapy. In addition, the drug was involved in trials for the treatment of preterm labor in obstetrical practice. Bedoradrine is also was studied in phase I of clinical trials for its use for treating chronic obstructive pulmonary disease, however, the efficacy for this disease was uncertain.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Beta-2 adrenergic receptor 209 Target ID: P07550\|\|\|Q53GA6\|\|\|Q9UCZ3 Gene ID: 154.0 Gene Symbol: ADRB2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/19527375	Agonist 2752

PubMed

Title	Date	PubMed
Investigation of beta(2)-adrenoceptor subtype selectivity and organ specificity for bedoradrine (KUR-1246), a novel tocolytic beta-adrenergic receptor stimulant.	2009-06	19527375
Effects of KUR-1246, a selective uterine relaxant, on transplacental passage and transmigration to milk.	2006-02	16445519
Cardiovascular effects of KUR-1246, a new tetrahydronaphthalen derivative beta2-adrenoceptor agonist and a selective uterine relaxant.	2006	16478001
Effects of long term administration of KUR-1246, a selective beta(2)-adrenoceptor agonist, on pregnant sheep and their fetuses.	2005-01	15663400
KUR-1246, a novel beta(2)-adrenoceptor agonist, as a tocolytic agent.	2002-09	12220768
Diversity of inhibitory responses to beta2-stimulants shown by term-pregnant human myometria in vitro is partly due to differences in receptor density.	2002-05	12015527
The practical synthesis of a uterine relaxant, bis(2-[[(2S)-2-([(2R)-2-hydroxy-2-[4-hydroxy-3-(2-hydroxyethyl)-phenyl]ethyl]amino)-1,2,3,4-tetrahydronaphthalen-7-yl]oxy]-N,N-dimethylacetamide) sulfate (KUR-1246).	2001-08	11515570

Patents

Sample Use Guides

In Vivo Use Guide

Initial dose: 16 μg/min for 15 minutes followed by 8 μg/min for 105 minutes (2-hour infusion with a total dose of 1,080 μg) Subsequent dose: 30 μg/min for 15 minutes followed by 15 μg/min for 45 minutes (1-hr infusion with a total dose of 1,125 μg).

Route of Administration: Intravenous

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:21:17 GMT 2025` Edited by `admin` on `Mon Mar 31 18:21:17 GMT 2025`
Record UNII	4EAR229231
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

KUR-1246 FREE BASE

Preferred Name

English

BEDORADRINE

Official Name

English

ACETAMIDE, N,N-DIMETHYL-2-(((7S)-5,6,7,8-TETRAHYDRO-7-(((2R)-2-HYDROXY-2-(4-HYDROXY-3-(2-HYDROXYETHYL)PHENYL)ETHYL)AMINO)-2-NAPHTHALENYL)OXY)-

Systematic Name

English

2-(((7S)-7-(((2R)-2-HYDROXY-2-(4-HYDROXY-3-(2-HYDROXYETHYL)PHENYL)ETHYL)AMINO)-5,6,7,8-TETRAHYDRONAPHTHALEN-2-YL)OXY)-N,N-DIMETHYLACETAMIDE

Systematic Name

English

MN-221 FREE BASE

Code

English

bedoradrine [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C48149